Abstract:Abstract Gliomas are the most common primary brain tumors. Glioblastoma multiforme (GBM), WHO grade IV, is the most frequent and aggressive form, with a median survival of approximately 12 months following aggressive treatment with surgical resection, radiation and chemotherapy. Epidermal growth factor receptor (EGFR) is frequently amplified and mutated in human cancers including GBM. While the rationale for treating GBM patients with EGR inhibitors is strong, the efficacy of anti-EGFR small molecular inhibitors or monoclonal antibodies in treating gliomas with PTEN mutation or deletion has been modest. Here we show a novel approach to inhibiting EGFR that involves a small molecule (G5-7) that selectively blocks JAK2 phosphorylation of EGFR, inhibits cell proliferation and reduces VEGF secretion, and leads to glioma shrinkage via apoptosis and anti-angiogenesis. G5-7 inhibited EGFR and STAT3 tyrosine phosphorylation by JAK2 through binding to its N-terminal FERM domain. Interestingly, G5-7 selectively inhibited the proliferation of U87MG/EGFRvIII cells and human GBM explant neurosphere cultures but only weakly affected U87MG/PTEN cells or normal neural progenitor cultures. Moreover, oral administration of this compound markedly diminishes the brain tumor volumes in both subcutaneous and intracranial models, supporting that this compound itself and/or the metabolites might be able to penetrate the brain-blood barrier and exert the anti-proliferative actions through blocking the oncogenic pathways in vivo. Chronic treatment of mice with 50 mg/kg G5-7 exhibits no obvious toxicity in the animals. Our finding demonstrates that G5-7 is a novel allosteric JAK2 inhibitor with potent anti-tumor activity for GBM. Our report not onlyidentify a novel drug for treating the GBM, but also provide insight into the molecular mechanisms of how these small molecules impinge on the EGFR/PTEN signaling. Optimization of these novel compounds will lead to new treatments for the patients with these devastating tumors. [K.H. and Q.Q. contributed equally to this work.] Citation Format: Kunyan He, Qi Qi, Chi-Bun Chan, Ge Xiao, Xia Liu, Carol Tucker-Burden, Liya Wang, Hui Mao, Xiang Lu, Frank E. McDonald, Hongbo Luo, Qi-wen Fan, William A. Weiss, Shi-yong Sun, Daniel J. Brat, Keqiang Ye. Blockade of glioma proliferation via allosteric inhibition of JAK2. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 5683. doi:10.1158/1538-7445.AM2013-5683

Induction of Cell-Cycle Arrest and Apoptosis in Glioblastoma Stem-Like Cells by WP1193, a Novel Small Molecule Inhibitor of the JAK2/STAT3 Pathway

Effect of A Small Molecule Inhibitor of the Jak2/Stat3 Pathway on Self-Renewal of Glioblastoma Stem Cells

A Noval STAT3 Pathway Inhibitor Suppresses the Self-renewal and Induces Apoptosis in Glioblastoma Stem Cells

Synthetic Lethality Through GSK3 Inhibition in Glioma Stem Cells Via the WNT-WWC1-YAP Axis

Induction of Autophagy in GSC by a STAT3 Pathway Inhibitor

Pyrimidine Compounds By4003 and By4008 Inhibit Glioblastoma Cells Growth Via Modulating Stat3 Signaling Pathway

Identification of Imidazo[4,5-C]pyridin-2-one Derivatives As Novel Src Family Kinase Inhibitors Against Glioblastoma.

Antitumor Activity Of Novel Pyrazole-Based Small Molecular Inhibitors Of The Stat3 Pathway In Patient Derived High Grade Glioma Cells

STEM-43. GSK3β PROMOTES THE BMX-MEDIATED STAT3 ACTIVATION TO MAINTAIN GLIOBLASTOMA STEM CELLS

Pyrimidine compounds BY4003 and BY4008 inhibit glioblastoma cells growth via modulating JAK3/STAT3 signaling pathway

Inhibition of Mesenchymal Phenotypes in Glioblastoma by Combined Targeting of NF-κB and STAT3 Pathways

Bromodomain inhibitor jq1 induces cell cycle arrest and apoptosis of glioma stem cells through the VEGF/PI3K/AKT signaling pathway

Abstract LB136: Characterization of a novel PI3Kinase inhibitor for treatment of glioblastoma multiforme

Dddr-39. Pi3 Kinase And Checkpoint Inhibition: A Potentially Novel Therapeutic Strategy For Glioblastoma (Gbm)

Glioblastoma Multiforme Stem Cell Cycle Arrest by Alkylaminophenol Through the Modulation of EGFR and CSC Signaling Pathways

Transcriptional CDK Inhibitors CYC065 and THZ1 Induce Apoptosis in Glioma Stem Cells Derived from Recurrent GBM

Increased interaction between connexin43 and microtubules is critical for glioblastoma stem-like cell maintenance and tumorigenicity

CCL2-targeted ginkgolic acid exerts anti-glioblastoma effects by inhibiting the JAK3-STAT1/PI3K-AKT signaling pathway

Blockade Of Glioma Proliferation Via Allosteric Inhibition Of Jak2

EGFR blockade in GBM brain tumor stem cells synergizes with JAK2/STAT3 pathway inhibition to abrogate compensatory mechanisms in vitro and in vivo

The potential use of tideglusib as an adjuvant radio-therapeutic treatment for glioblastoma multiforme cancer stem-like cells